Geroscience in the age of COVID-19

Nir Barzilai; James C. Appleby; Steven N. Austad; Ana Maria Cuervo; Matt Kaeberlein; Christian Gonzalez-Billault; Stephanie Lederman; Ilia Stambler; Felipe Sierra

doi:10.14336/AD.2020.0629

Geroscience in the age of COVID-19

Nir Barzilai, James C. Appleby, Steven N. Austad, Ana Maria Cuervo, Matt Kaeberlein, Christian Gonzalez-Billault, Stephanie Lederman, Ilia Stambler, Felipe Sierra

Research output: Contribution to journal › Review article › peer-review

22 Scopus citations

Abstract

The data on COVID-19 is clear on at least one point: Older adults are most vulnerable to hospitalization, disability and death following infection with the novel coronavirus. Therefore, therapeutically addressing degenerative aging processes as the main risk factors appears promising for tackling the present crisis and is expected to be relevant when tackling future infections, epidemics and pandemics. Therefore, utilizing a geroscience approach, targeting aging processes to prevent multimorbidity, via initiating broad clinical trials of potential geroprotective therapies, is recommended.

Original language	English (US)
Pages (from-to)	725-729
Number of pages	5
Journal	Aging and Disease
Volume	11
Issue number	4
DOIs	https://doi.org/10.14336/AD.2020.0629
State	Published - 2020

Keywords

Aging biomarkers
COVID-19
Geroprotectors
Geroscience
Immunosenescence

ASJC Scopus subject areas

Pathology and Forensic Medicine
Geriatrics and Gerontology
Clinical Neurology
Cell Biology

Access to Document

10.14336/AD.2020.0629

Cite this

@article{2c3a7869327f4c8c8ae616d00480f182,

title = "Geroscience in the age of COVID-19",

abstract = "The data on COVID-19 is clear on at least one point: Older adults are most vulnerable to hospitalization, disability and death following infection with the novel coronavirus. Therefore, therapeutically addressing degenerative aging processes as the main risk factors appears promising for tackling the present crisis and is expected to be relevant when tackling future infections, epidemics and pandemics. Therefore, utilizing a geroscience approach, targeting aging processes to prevent multimorbidity, via initiating broad clinical trials of potential geroprotective therapies, is recommended.",

keywords = "Aging biomarkers, COVID-19, Geroprotectors, Geroscience, Immunosenescence",

author = "Nir Barzilai and Appleby, {James C.} and Austad, {Steven N.} and Cuervo, {Ana Maria} and Matt Kaeberlein and Christian Gonzalez-Billault and Stephanie Lederman and Ilia Stambler and Felipe Sierra",

note = "Publisher Copyright: {\textcopyright} 2020 Barzilai N, et al.",

year = "2020",

doi = "10.14336/AD.2020.0629",

language = "English (US)",

volume = "11",

pages = "725--729",

journal = "Aging and Disease",

issn = "2152-5250",

publisher = "International Society on Aging and Disease",

number = "4",

}

TY - JOUR

T1 - Geroscience in the age of COVID-19

AU - Barzilai, Nir

AU - Appleby, James C.

AU - Austad, Steven N.

AU - Cuervo, Ana Maria

AU - Kaeberlein, Matt

AU - Gonzalez-Billault, Christian

AU - Lederman, Stephanie

AU - Stambler, Ilia

AU - Sierra, Felipe

PY - 2020

Y1 - 2020

N2 - The data on COVID-19 is clear on at least one point: Older adults are most vulnerable to hospitalization, disability and death following infection with the novel coronavirus. Therefore, therapeutically addressing degenerative aging processes as the main risk factors appears promising for tackling the present crisis and is expected to be relevant when tackling future infections, epidemics and pandemics. Therefore, utilizing a geroscience approach, targeting aging processes to prevent multimorbidity, via initiating broad clinical trials of potential geroprotective therapies, is recommended.

AB - The data on COVID-19 is clear on at least one point: Older adults are most vulnerable to hospitalization, disability and death following infection with the novel coronavirus. Therefore, therapeutically addressing degenerative aging processes as the main risk factors appears promising for tackling the present crisis and is expected to be relevant when tackling future infections, epidemics and pandemics. Therefore, utilizing a geroscience approach, targeting aging processes to prevent multimorbidity, via initiating broad clinical trials of potential geroprotective therapies, is recommended.

KW - Aging biomarkers

KW - COVID-19

KW - Geroprotectors

KW - Geroscience

KW - Immunosenescence

UR - http://www.scopus.com/inward/record.url?scp=85090655079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090655079&partnerID=8YFLogxK

U2 - 10.14336/AD.2020.0629

DO - 10.14336/AD.2020.0629

M3 - Review article

AN - SCOPUS:85090655079

SN - 2152-5250

VL - 11

SP - 725

EP - 729

JO - Aging and Disease

JF - Aging and Disease

IS - 4

ER -

Geroscience in the age of COVID-19

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this